RP G28

Drug Profile

RP G28

Alternative Names: RP-G28

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ritter Pharmaceuticals
  • Developer Ritter Pharmaceuticals; University of British Columbia
  • Class Digestion aids; Oligosaccharides
  • Mechanism of Action Bacterial growth stimulants; Carbohydrate metabolism stimulants; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Lactose intolerance
  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 27 Jun 2018 Phase-III clinical trials in Lactose intolerance in USA (PO)
  • 05 Jun 2018 Updated efficacy data from a phase IIb/III trial in Lactose intolerance released by Ritter Pharmaceuticals
  • 02 Jun 2018 Updated efficacy data from a phase II/III trial in Lactose intolerance presented at the Digestive Disease Week 2018 (DDW-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top